Buy Avanafil online in Ireland – fast, discreet & affordable

Avanafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that enhances nitric oxide–dependent relaxation in the corpus cavernosum by increasing cyclic GMP (cGMP) levels. It is a member of the PDE5 inhibitor class and is indicated for the treatment of erectile dysfunction.

What Avanafil is

Pharmacologic class and mechanism: Avanafil selectively inhibits PDE5, reducing cGMP breakdown in penile tissue. Sexual stimulation triggers nitric oxide release, leading to cGMP accumulation and smooth muscle relaxation, enabling penile erection. Onset of action is typically rapid, with noticeable effect within 15–30 minutes in many patients, and the effect may last several hours.

Pharmacokinetics and formulation: Avanafil is rapidly absorbed, with peak plasma concentration in about 30–45 minutes. It is metabolized primarily by hepatic CYP3A4 and to a lesser extent by other CYP enzymes, with excretion via feces and urine. The drug is available as oral film-coated tablets and may be taken with or without food, though a high-fat meal can delay onset. Dosing is on-demand unless otherwise prescribed.

Clinical context: In routine practice, Avanafil is used on-demand prior to anticipated sexual activity. It does not produce an automatic erection and requires sexual stimulation. It is not approved for daily prophylaxis unless a specific regimen is prescribed.

What it is used for

Indication and purpose: Avanafil is indicated for the treatment of erectile dysfunction in adult men. It facilitates erection only in the presence of sexual arousal and is not a curative therapy for underlying conditions causing ED. It is not indicated for female sexual dysfunction.

Clinical scope and limitations: Efficacy may vary with comorbidity, obesity, or concurrent medications. Food intake can influence onset timing, and adherence to timing recommendations enhances responsiveness. It is not a substitute for other medical treatments when ED is secondary to untreated medical disease.

Usage considerations: The medication is intended for on-demand use and should be taken only as prescribed. It is not a substitute for lifestyle modification or management of cardiovascular risk factors that may contribute to erectile dysfunction.

Contraindications and precautions

Contraindications: Avanafil is contraindicated in patients taking nitrates or nitrite therapy for chest pain or heart failure. Concomitant use can produce severe hypotension. Use with riociguat or other soluble guanylate cyclase stimulators is also contraindicated.

Cardiovascular and hemodynamic precautions: Caution is warranted in patients with hypotension or uncontrolled hypertension, with recent stroke or myocardial infarction, or with significant aortic stenosis. Initiation and dosing should consider coexisting antihypertensive therapy to minimize orthostatic effects.

Ocular and other safety considerations: There is a rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) with PDE5 inhibitors; patients with a history of NAION or vascular risk factors should be advised to seek prompt evaluation if vision changes occur. Caution is advised in those with retinal disorders or significant sensory impairment.

Side effects by frequency

Common adverse effects: Headache, flushing, nasal congestion, dizziness, dyspepsia, back pain. These events are usually mild to moderate and resolve with continued therapy or dose adjustment.

Uncommon adverse effects: Hypotension, fainting, palpitations, blurred or altered color vision, and myalgias. Some patients may experience transient vertigo or throat irritation.

Rare adverse effects: Priapism and sudden sensorineural hearing loss have been reported rarely. Severe cutaneous reactions or hypersensitivity events are uncommon but require discontinuation and medical evaluation if they occur.

Interactions with other substances

Nitrates and nitrites: Concomitant use is contraindicated due to risk of profound hypotension. Do not combine with organic nitrates in any form. Riociguat and other guanylate cyclase stimulators are also contraindicated with PDE5 inhibitors.

Other cardiovascular drugs: Simultaneous use with alpha-blockers or other antihypertensives may cause symptomatic hypotension. If combination is necessary, initiate Avanafil at the lowest effective dose and monitor blood pressure and symptoms closely.

Pharmacokinetic interactions: Avanafil is metabolized by CYP3A4; strong inhibitors (eg, ketoconazole, ritonavir) increase exposure and may require dose adjustment or avoidance. Inducers (eg, rifampin) decrease exposure and may reduce efficacy. Grapefruit juice can modestly affect levels; caution is advised.